Jump to content

Recommended Posts

Posted
11 hours ago, Harrison Stafford said:

Here you go.  In addition, the European Medicines Agency accepted IBRX’s application of Anktiva for the treatment of patients with bladder cancer.  This application covers 30 countries in the EU.  Now, just waiting on approval.  Big Pharma (looking at you, Merck) will most def try to buy IBRX at a hefty premium.  Patrick Soon-Shiong, who owns 80% of IBRX, is 72 years old and ain’t getting any younger.  Hit him with an uber aggressive offer and he might just bite. PSS also has the track record of building up a company and selling to big Pharma for big bucks.  

Let hope that aggressive offer comes after it is back in double digits and not at $4.

  • Hook 'Em 2

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.



×
×
  • Create New...